Sweden's C-Rad Q2 revenue rises as EMEA drives growth
Sweden's C-Rad Q2 revenue rises as EMEA drives growth
Overview
Sweden surface-guided imaging firm's Q2 revenue rose 16%, driven by strong EMEA performance
Order intake fell 15% in Q2, mainly due to weaker Americas performance
Company completed restructuring program, expects annual savings to support growth
Outlook
Company says focus now shifts to accelerating commercial growth, innovation and profitability
C-RAD to prioritize investments in software, innovation, partnerships and recurring service revenues
Company expects annual savings of MSEK 20 from restructuring, with full effect by year-end
Result Drivers
EMEA GROWTH - Revenue increase was primarily driven by continued strong performance in EMEA
PROTON DELIVERIES - Gross margin improvement was mainly due to proton therapy deliveries
SERVICES SEGMENT - Services segment achieved organic growth of 15%, supporting recurring revenues
Company press release: ID:nMFN7mrD9x
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| SEK 0.72 |
|
Q2 Net Income |
| SEK 24 mln |
|
Q2 EBIT |
| SEK 38 mln |
|
Analyst Coverage
The one available analyst rating on the shares is "buy"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
The stock recently traded at 19 times the next 12-month earnings vs. a P/E of 11 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)